NEUROENDOCRINE TUMORS
Clinical trials for NEUROENDOCRINE TUMORS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMORS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough prostate cancers
Disease control CompletedThis study tested a new oral drug, BXCL701, combined with the immunotherapy pembrolizumab for men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could help control the cancer. It focuse…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: PHASE1, PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug duo tested for Tough-to-Treat neuroendocrine cancers
Disease control CompletedThis study tested whether combining two existing cancer drugs, pembrolizumab and lenvatinib, could help control advanced neuroendocrine tumors that had worsened despite previous treatments. It involved 20 adults whose cancer had spread and was still growing. The main goals were t…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Tiny radioactive beams aim to zap liver tumors in new trial
Disease control CompletedThis study tested a targeted radiation treatment for people with neuroendocrine cancer that had spread to the liver and could not be removed by surgery. Doctors injected tiny radioactive beads directly into the liver's blood supply to deliver high-dose radiation to the tumors whi…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial tests hope for Hard-to-Treat tumors
Disease control CompletedThis study tested a drug called surufatinib in Japanese patients with advanced neuroendocrine tumors that had stopped responding to standard treatments. The first part checked the drug's safety and the best dose, while the second part measured how well it shrank tumors. A total o…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Scientists track patients for years after experimental cancer treatment
Disease control CompletedThis study monitored 20 patients who had previously received an experimental treatment called 177Lu-satoreotide tetraxetan for neuroendocrine tumors. Researchers tracked their long-term health to check for any delayed side effects or new cancers that might be related to the treat…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: NA • Sponsor: Ariceum Therapeutics GmbH • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Researchers check biopsy Needle's performance in cancer diagnosis
Knowledge-focused CompletedThis study aimed to gather more information about how well a specific biopsy needle works during a common diagnostic procedure. Doctors used the EchoTip AcuCore needle to collect tissue samples from 183 adults with various cancers or pancreatic conditions. The main goal was to se…
Matched conditions: NEUROENDOCRINE TUMORS
Sponsor: Cook Research Incorporated • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC
-
Researchers investigate survival patterns for aggressive digestive tumors
Knowledge-focused CompletedThis study analyzed existing medical records to understand how a rare, aggressive type of digestive neuroendocrine tumor behaves and responds to different chemotherapy treatments. Researchers looked at data from 168 adult patients in France who had this specific tumor type. The g…
Matched conditions: NEUROENDOCRINE TUMORS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC
-
Tumor test could match patients to best chemo, study finds
Knowledge-focused CompletedThis study aimed to see if a specific marker in a tumor (called MGMT) can predict which type of chemotherapy works better for patients with advanced neuroendocrine tumors. Researchers tested 116 patients to see if those with a 'methylated' MGMT marker responded better to one clas…
Matched conditions: NEUROENDOCRINE TUMORS
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC